Gastric Cancer Clinical Trials in Tianjin

7 recruitingTianjin, China

Showing 17 of 7 trials

Recruiting
Phase 3

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled284 locationsNCT06764875
Recruiting
Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric CancerGastroesophageal-junction Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled230 locationsNCT07431281
Recruiting

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo260 enrolled36 locationsNCT06846996
Recruiting

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Gastric CancerImagePathology
Chinese Academy of Sciences200 enrolled22 locationsNCT06035250